For research use only, not for therapeutic use.
Cidofovir dihydrate (CAT: I001840) is a potent antiviral medication used primarily for the treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, such as those with AIDS. It is a nucleotide analog that inhibits viral DNA replication by incorporating into the growing DNA chain and terminating its elongation. Cidofovir dihydrate has also shown activity against other DNA viruses, including herpes simplex viruses (HSV) and human papillomaviruses (HPV). It is typically administered intravenously and may be associated with side effects such as nephrotoxicity. Cidofovir dihydrate is a valuable tool in the management of CMV retinitis and other viral infections in certain patient populations.
Catalog Number | I001840 |
CAS Number | 149394-66-1 |
Molecular Formula | C8H18N3O8P |
Purity | ≥95% |
Target | CMV DNA polymerase |
Solubility | 10 mM in DMSO |
Storage | Store at -20°C |
Related CAS | 113852-37-2(anhydrous) |
SMILES | n1(C[C@H](OCP(=O)(O)O)CO)c(=O)nc(cc1)N.O.O |
Reference | 1: Lalezari JP, Drew WL, Glutzer E, James C, Miner D, Flaherty J, Fisher PE, 2: Kirsch LS, Arevalo JF, De Clercq E, Chavez de la Paz E, Munguia D, Garcia R, <br> 4: James JS. Cidofovir recommended for approval for CMV retinitis. AIDS Treat 5: de Oliveira CB, Stevenson D, LaBree L, McDonnell PJ, Trousdale MD. Evaluation |